M
Maria R. Mattiacci
Researcher at Merck Serono
Publications - 2
Citations - 70
Maria R. Mattiacci is an academic researcher from Merck Serono. The author has contributed to research in topics: Cyclophosphamide & Lymphocyte. The author has an hindex of 2, co-authored 2 publications receiving 57 citations.
Papers
More filters
Journal ArticleDOI
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Silke Gillessen,Ulrike Gnad-Vogt,Elisa Gallerani,Joachim Beck,Cristiana Sessa,Aurelius Omlin,Maria R. Mattiacci,Bernd Liedert,Daniel Kramer,Julien Laurent,Julien Laurent,Daniel E. Speiser,Roger Stupp +12 more
TL;DR: Selectikine had a favourable safety profile and induced biological effects typical for IL-2, and was investigated in this first-in-human phase I study of cancer treatment of metastatic or locally advanced solid tumours.
Journal ArticleDOI
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
Joseph P. Connor,Mihaela C. Cristea,Nancy L. Lewis,Lionel D. Lewis,Philip B Komarnitsky,Maria R. Mattiacci,Mildred Felder,Sarah L. Stewart,Josephine Harter,Jean Henslee-Downey,Daniel Kramer,Roland Neugebauer,Roger Stupp +12 more
TL;DR: The combination of huKS-IL2 with low-dose cyclophosphamide was well tolerated and showed evidence of immunologic activity, and 3 patients showed stable disease for ≥ 4 cycles.